A5110156508- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Biosimilars and Bioanalytical Methods
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Chemotherapy-related skin toxicity
- Head and Neck Cancer Studies
- Cancer therapeutics and mechanisms
- Multiple Myeloma Research and Treatments
- Phagocytosis and Immune Regulation
- Nutrition and Health in Aging
- Cancer-related Molecular Pathways
Ruby Hall Clinic
2013-2025
Washington DC VA Medical Center
2024-2025
Noble Hospital
2011-2024
Interfaith Medical Center
2024
George Washington University
2024
Midas Multispeciality Hospital
2024
Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals
2023
Tata Memorial Hospital
2015
GlaxoSmithKline (United Kingdom)
2015
Institut Gustave Roussy
2015
A global unmet medical need exists for effective treatments persistent, recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently, immunotherapies shown promising survival benefits with advanced forms of cancer. Axalimogene filolisbac (ADXS11-001), Listeria monocytogenes immunotherapy broad effect on the immune system, is under investigation treatment human papillomavirus-associated cancers including cancer.This phase 2 study evaluated safety and efficacy...
BackgroundAfatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade afatinib plus paclitaxel superior outcomes versus switching to chemotherapy alone acquiring resistance erlotinib/gefitinib and monotherapy.Patients methodsPatients relapsed/refractory disease following ≥1 line of chemotherapy, whose tumors had progressed...
This multicenter phase III study evaluated the efficacy and safety of lapatinib, an epidermal growth factor receptor/ErbB2 inhibitor, administered concomitantly with chemoradiotherapy as maintenance monotherapy in patients high-risk surgically treated squamous cell carcinoma head neck (SCCHN).Patients resected stage II to IVA SCCHN, a surgical margin ≤ 5 mm and/or extracapsular extension, were randomly assigned (66 Gy total radiation dose cisplatin 100 mg/m(2) per day on days 1, 22, 43) plus...
Background Global phase III trials demonstrated efficacy of abemaciclib in patients with HR +/HER2– metastatic breast cancer (BC) as a first-line therapy combination nonsteroidal aromatase inhibitor (MONARCH-3) or fulvestrant following progression after endocrine (ET) (MONARCH-2). However, there is limited data on safety and tolerability plus ET the BC setting among Indian patients, which present study aims to address. Materials Methods An open-label, single-arm, IV was conducted across 16...
Abstract Lorlatinib is approved in India for patients with previously treated anaplastic lymphoma kinase (ALK)–positive advanced or recurrent non-small-cell lung cancer (NSCLC). Owing to the limited number of Indian phase I/II and III studies, a postapproval study was conducted report safety efficacy lorlatinib this patient population. In IV study, unresectable and/or ALK-positive NSCLC resistant intolerant ≥1 prior ALK inhibitor were lorlatinib. The primary endpoint investigator-assessed...
Background: Next-generation sequencing has revealed TP53 alterations in localized prostate cancer (PCa), suggesting growing clinical potential for p53 immunohistochemistry (IHC). Prior research supports the use of IHC detection overexpression to predict presence known be associated with adverse outcomes. However, reach a consensus definition PCa, further insights are needed. This study aimed compare two fundamental approaches evaluating expression across variety specimens regarding PCa...
AIMS: Cachexia, the wasting disorder associated with a wide range of serious illnesses including cancer, is major cause morbidity and mortality. There currently no widely approved therapeutic agent for treating or preventing cancer-associated cachexia. Colorectal cancer non-small cell lung have relatively high incidences cachexia, approximately 28% 34%, respectively. Neurohormonal overactivity has been implicated in genesis progression cachexia beta receptor antagonism proposed as potential...
Paclitaxel is widely used in the treatment of patients with metastatic breast cancer (MBC). Formulations paclitaxel contain surfactants and solvents or albumin derived from human blood. The use co-solvents such as polyoxyethylated castor oil thought to contribute toxicity profile hypersensitivity reactions well leaching plasticizers polyvinyl chloride bags infusion sets. Currently, nab-paclitaxel, an albumin-bound nanometer range continues be preferred taxane formulation clinic. This study...
5610 Background: ADXS11-001 immunotherapy is a live attenuated Listeria monocytogenes (Lm) bioengineered to secrete HPV-16-E7 fusion protein targeting HPV transformed cells. The Lm vector serves as its own adjuvant and infects APC where it cross presents, stimulating MHC class 1 2 pathways resulting in specific T-cell immunity tumors. Here we describe final results from Lm-LLO-E7-015, randomized P2 study designed evaluate the safety efficacy of with without cisplatin 110 patients recurrent...
Abstract Introduction: SOR is a targeted therapeutic agent indicated for advanced renal cell carcinoma and hepatocellular carcinoma. targets multiple kinases involved in tumor growth angiogenesis. The TIES (Trials to Investigate the Effects of Sorafenib BC) program includes 4 phase 2b randomized, double-blind, placebo-controlled screening trials HER2-negative BC. Recently, first these trials, SOR+capecitabine (CAP) vs placebo (PL)+CAP demonstrated significant progression-free survival (PFS)...
6005 Background: Epidermal growth factor receptor (EGFR) and ErbB2 are overexpressed in up to 90% 40% of SCCHN, respectively. L, a tyrosine kinase inhibitor (TKI) both EGFR ErbB2, demonstrates tumor responses SCCHN. Methods: Patients with resected stage II-IVA surgical margin ≤5mm and/or extracapsular extension were randomized CT-RT either P or L. RT was 66Gy (2Gy per day, 5 days week).100 mg/m2of cisplatin administered on 1, 22 43 RT. L 1500 mg/day given for one week prior CT-RT, during 12...
Meeting abstracts ADXS11-001 immunotherapy is a live attenuated Listeria monocytogenes ( Lm ) bioengineered to secrete tLLO-HPV-16-E7 fusion protein targeting HPV-transformed cells. The vector serves as its own adjuvant and infects APC where it cross presents HPV-E7-tLLO peptide,
A retrospective survival benefit analysis of APCEDEN®, APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management refractory solid malignancies, was performed in comparison with a control group.Subjects (retrospective data) whose data, geographical region, age, gender, ECOG performance status and stage disease that could be matched the treatment group were considered analysis.The suggests significant 199 days...
Abstract Purpose Resistance to HER2 (ErbB2)-targeted therapy may be mediated by other members of the ErbB family. We investigated efficacy and safety irreversible family blocker, afatinib, alone as first-line in advanced setting combination with vinorelbine or paclitaxel for those who progressed on afatinib monotherapy, female patients metastatic breast cancer had failed prior HER2-targeted early disease setting. Methods In this phase II, single-arm, two-part study (ClinicalTrials.gov:...
PURPOSE Squamous cell carcinoma of the head and neck (SCCHN) is sixth most common cancer, with approximately 225,419 new cases over 125,000 deaths annually in India. This trial compared efficacy safety biosimilar cetuximab versus innovator (IC) combination platinum-based chemotherapy patients recurrent locoregional or metastatic SCCHN. METHODS phase III a multicenter, randomized, double-blind parallel group study performed Indian Patients were randomly assigned 2:1 ratio to receive IC...
Abstract Background: Sorafenib (SOR) is an oral multikinase inhibitor that targets tumor growth and angiogenesis. We previously reported progression-free survival (PFS) data from the primary analysis of NU07B1 (SABCS 2009 abstr 44), a phase 2b trial assessing combination SOR + paclitaxel (PAC) in patients with advanced breast cancer (BC). Here we report overall (OS) data, secondary endpoint. Methods: multinational (India, United States, Brazil) study HER2-negative locally or metastatic BC....
3011 Background: Cyclin-dependent kinases (Cdks) have emerged as important targets in anticancer drug development. P1446A-05 is a potent and specific inhibitor of Cdk4-D1 (IC 50 -0.09µM), Cdk1-B -0.025µM), Cdk9-T -0.022µM). This study was designed to determine the maximum tolerated dose (MTD), limiting toxicity (DLT), safety profile, pharmacokinetics, antitumor activity orally administered patients with advanced refractory tumors. Methods: conducted at 5 centers India. escalating doses...
8056 Background: Belagenpumatucel-L (Lucanix) is a therapeutic vaccine comprised of 4 TGF-β2 antisense gene-modified, irradiated, allogeneic NSCLC cell lines. Methods: The trial enrolled patients (pts) without progression after completion frontline chemotherapy (IIIA-42, IIIB/IV-490). Pts were randomized 1:1 between and 17.4 weeks (w) from the end chemotherapy. treated until disease or withdrawal. primary endpoint was overall survival (OS). Secondary endpoints PFS, RR safety. Results: 532...